PCG
PLRX icon

Private Capital Group’s Pliant Therapeutics PLRX Stock Holding History

Private Capital Group’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-197
Closed -$1K – 2056
2022
Q1 		$1K Buy
+197
New +$2.01K ﹤0.01% 1985

Other funds holding PLRX

TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $4.26B AUM 5.81% 1-Year Est. Return

Private Capital Group's PLRX Position: Q2 2022 in Review

Private Capital Group sold out of Pliant Therapeutics (PLRX) in Q2 2022, closing a stake of 197 shares — an estimated $1K sold.

Private Capital Group first reported a position in PLRX in Q1 2022 and held it in 1 quarter. The position peaked at $1K in Q1 2022. 88 funds tracked by Wall St. Rank hold PLRX as of Q2 2022.

  • Private Capital Group reported no remaining Pliant Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Private Capital Group sold 197 Pliant Therapeutics shares in Q2 2022, an estimated $1K.
  • Private Capital Group first reported a position in Pliant Therapeutics in Q1 2022 and held it in 1 quarter.
  • Private Capital Group's Pliant Therapeutics position peaked at $1K in Q1 2022.
  • 88 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q2 2022.

Based on Private Capital Group's 13F filing for Q2 2022, filed 28 Jul 2022.